Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab step-up priming and extended-interval monotherapy in relapsed/refractory multiple myeloma
jRCT2051210103Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Primary endpoint: Proportion of participants with Grade 2 or higher Cytokine Release Syndrome. Started Nov 2021; status: completed.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2051210103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210103.